Phase I clinical trials are now ongoing at the Memorial Sloan-Kettering Cancer
Center and the University of Alabama using the immuno-conjugate BR96-Dox, for
the treatment of malignent solid tumors expressing the Lewis y antigen. These
are NCI-sponsored trials.
To date, no information has been published on the results of these clinical
trials. Any information, preliminary or otherwise, would be appreciated.
